Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer, Brain Cancer, Neurology |
| Therapuetic Areas: | Neurology, Oncology |
| Healthy: | No |
| Age Range: | 4 - 21 |
| Updated: | 5/20/2018 |
| Start Date: | October 13, 2015 |
| End Date: | March 31, 2022 |
| Contact: | Stephanie Perkins, M.D. |
| Email: | sperkins@wustl.edu |
| Phone: | 314-747-4405 |
This study will explore neurocognitive performance in pediatric brain tumor patients
receiving proton beam radiation therapy (PBRT). The investigators goal is to gather baseline
neurocognitive testing prior to the completion of the first week of radiation therapy along
with follow-up testing 6-12 months after the completion of radiation and serial annual
testing thereafter. With these data the investigators plan to evaluate the effects of PBRT on
neurocognitive performance as it relates to patients' age at diagnosis, tumor location, and
radiation dose. Modeling studies have demonstrated that PBRT could improve neurocognitive
outcomes, but there is a paucity of prospectively-collected patient data. The investigators
are uniquely positioned to address this important question given the busy pediatric central
nervous system (CNS) tumor service, the delivery of proton therapy at the S. Lee Kling Proton
Therapy Center at Barnes-Jewish Hospital, and the multi-disciplinary research team with
extensive experience into the late effects of therapy as it relates to neurocognition.
receiving proton beam radiation therapy (PBRT). The investigators goal is to gather baseline
neurocognitive testing prior to the completion of the first week of radiation therapy along
with follow-up testing 6-12 months after the completion of radiation and serial annual
testing thereafter. With these data the investigators plan to evaluate the effects of PBRT on
neurocognitive performance as it relates to patients' age at diagnosis, tumor location, and
radiation dose. Modeling studies have demonstrated that PBRT could improve neurocognitive
outcomes, but there is a paucity of prospectively-collected patient data. The investigators
are uniquely positioned to address this important question given the busy pediatric central
nervous system (CNS) tumor service, the delivery of proton therapy at the S. Lee Kling Proton
Therapy Center at Barnes-Jewish Hospital, and the multi-disciplinary research team with
extensive experience into the late effects of therapy as it relates to neurocognition.
Inclusion Criteria:
- Diagnosis of primary CNS tumor or diagnosis of metastatic disease to the CNS with an
expected overall survival of > 1 year. Any prior treatment (chemo, XRT, or surgery) is
allowed.
- Planning to receive PBRT to treat the CNS tumor. Patients who have already received
PBRT for this disease may also be enrolled provided they completed the NIH Toolbox
Cognitive Battery prior to the first week of radiation therapy.
- Between 4 and 21 years of age (inclusive).
- Life expectancy of at least one year.
- Absence of visual impairment that would impede computer testing.
- No secondary health conditions that would impact cognitive functioning (e.g.
psychiatric or developmental disability unrelated to cancer).
- Able to understand and willing to sign IRB-approved written informed consent document
(or signature of legally authorized representative).
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Stephanie Perkins, M.D.
Phone: 314-747-4405
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
